What Has Been the Progress and Growth of the Therapeutic Drug Monitoring Market in Recent Years?
The therapeutic drug monitoring market has seen considerable growth due to a variety of factors.
•The market size for therapeutic drug monitoring has experienced robust growth lately. It is forecasted to expand from $2.23 billion in 2024 to $2.43 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%.
This substantial growth in the historical period has been driven by factors such as increased prevalence of chronic illnesses, heightened concern for drug safety, the incorporation of pharmacogenomics, an upsurge in drug development, and regulatory focus on precision medicine.
What Can Be Expected from the Therapeutic Drug Monitoring Market in the Coming Years?
The therapeutic drug monitoring market is expected to maintain its strong growth trajectory in upcoming years.
• There is an expected swift expansion in the therapeutic drug monitoring market in the coming years, with growth forecasted to reach $3.72 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.3%.
This upward trend during the forecast period is likely due to factors such as, wider oncology applications, the rising trends of personalized medicine, an increased aging population globally, expanded point-of-care testing, and a surge in pharmaceutical research and development expenditure. Key trends during this period include personalized medicine, advances in technology, a surge in drug development and consumption, point-of-care testing (POCT), as well as the emergence of new biomarkers and assay technologies.
What Main Forces Are Fueling Expansion In The Therapeutic Drug Monitoring Market?
The therapeutic drug monitoring market is anticipated to surge due to an increase in the number of organ transplant surgeries. Organ transplant is a procedure that involves relocating an organ from one person (the donor) to another. The management of patients undergoing solid organ transplantation has been effectively handled using therapeutic drug monitoring (TDM) of immunosuppressive drugs. TDM optimization can prevent harmful or inadequately low-dose therapy which could lead to organ rejection. For example, in January 2023, the United Network for Organ Sharing, an American non-profit organization that oversees organ transplants, published an article stating that in 2022, 42,887 organ transplants took place in the US, marking a 3.7% rise from 2021. Therefore, the therapeutic drug monitoring market is being fueled by the increasing trend in organ transplant surgeries.
What Are The Primary Segments In The Global Therapeutic Drug Monitoring Market?
The therapeutic drug monitoring market covered in this report is segmented –
1) By Product: Consumables, Equipment, Immunoassay Analyzers, Chromatography And Detectors
2) By Technology: Immunoassays, Chemiluminescence Immunoassays, Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, Radioimmunoassay, Other Immunoassays, Chromatography-Ms, Lc-Ms, Gc-Ms
3) By Class Of Drug: Antiepileptic Drugs, Antibiotic Drugs, Immunosuppressant Drugs, Antiarrhythmic Drugs, Bronchodilator Drugs, Psychoactive Drugs, Other Drugs
4) By End-user: Hospital Laboratories, Commercial and Private Laboratories, Other End Users
Subsegments:
1) By Consumables: Reagents, Test Kits, Sample Collection Containers, Calibration Standards
2) By Equipment: Analyzers, Incubators, Centrifuges, Other Equipment
3) By Immunoassay Analyzers: ELISA Analyzers, Chemiluminescent Immunoassay Analyzers, Radioimmunoassay Analyzers
4) By Chromatography And Detectors: High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), Other Chromatography Techniques
Pre-Book The Therapeutic Drug Monitoring Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Therapeutic Drug Monitoring Market?
Key players in the therapeutic drug monitoring market are prioritizing the advancement of anti-idiotypic antibody technology to increase the precision and reliability of assays for the effective measurement of biologic drug volumes and patient immune responses evaluation. The anti-idiotypic antibody technology provides an advantage in therapeutic drug monitoring by facilitating meticulous detection and quantification of biologic drug levels, verifying correct dosage, and monitoring of patient immune reactions. For example, Bio-Rad Laboratories, an American biotech firm, in June 2024, introduced novel anti-idiotypic and anti-monomethyl auristatin E (MMAE) antibodies for bioanalytical assays, boosting pharmacokinetic (PK) and antidrug-antibody (ADA) tracking. These innovative antibodies significantly improve the dependability of assays for antibody-drug conjugates (ADCs) and play a pivotal role in the therapeutic drug monitoring market, allowing for precise evaluations of drug levels and immune reactions for suitable patient dosing.
Who Are the Key Players in the Therapeutic Drug Monitoring Market?
Major companies operating in the therapeutic drug monitoring market include:
• Abbott Laboratories Inc.
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Sekisui Medical Co.
• Buehlmann Laboratories AG
• Danaher Corporation
• Bio-Rad Laboratories Inc.
• bioMérieux SA
• Randox Laboratories Limited
• Chromsystems Instruments & Chemicals GmbH
• Grifols SA
• Merck KGaA
• BioChem Pharmaceuticals
• Beckman Coulter Inc.
• DiaSorin S.p.A.
• Hologic Inc.
• Immunodiagnostic Systems Holdings plc
• Kronus Inc.
• QuidelOrtho Corporation
• Sysmex Corporation
• TDM Solutions Inc.
• Theradiag
• Tosoh Bioscience LLC
• Trinity Biotech plc
• Associated Regional and University Pathologists Inc.
• Mayo Clinic Laboratories
• Quest Diagnostics
What Is The Most Dominant Region In The Therapeutic Drug Monitoring Market?
North America was the largest region in the therapeutic drug monitoring market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global therapeutic drug monitoring market report during the forecast period. The regions covered in the therapeutic drug monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
